Novartis agrees to pay $30 million to resolve end-payors' US antitrust claims over Exforge
MLex Summary: Novartis Pharmaceuticals agreed to pay $30 million to resolve US antitrust claims filed by end-payors of the hypertension drug Exforge accusing it of conspiring to delay a generic competitor....To view the full article, register now.
Already a subscriber? Click here to view full article